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Abstract
Background The H1-antihistamine cetirizine, a piperazine derivative widely used in daily 
practice, is rarely the cause of cutaneous drug reaction. Nevertheless, four cases of fixed drug 
eruption (FDE) as a result of this drug have been described recently. We present the case of a 
45-year-old woman with a multilocalized FDE following oral intake of cetirizine for allergic 
rhinitis.
Methods Patch testing with hydroxyzine 1% and 10% in petrolatum (Chemotechnique), and 
with powdered Zyrtec® (cetirizine) and Xyzal® (levocetirizine) pills, prepared at 20% in water 
and at 20% in petrolatum, was performed in both residual lesions and healthy skin.
Results Positive results (++) to these drugs (24 h occlusion and readings at days 2 and 3) were 
obtained in residual lesions only. These results allowed us to confirm the drug responsible for 
this FDE and to study cross-reactions between antihistamines of the same chemical family.
Conclusions To the best of our knowledge, this is the first report of FDE to cetirizine with 
positive patch testing to hydroxyzine, cetirizine, and levocetirizine. This case highlights the 
importance of patch testing in the study of cutaneous drug reactions, namely FDE.
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H1-antihistamine drugs, widely used in the treatment of aller-
gic diseases, have an excellent safety profile, particularly
those of the second and third generations. Cutaneous side-
effects, such as fixed drug eruption (FDE), are very un-
common, and only a few cases have been described. Patch testing
is not regularly performed, because re-challenge with the
reappearance of skin lesions identifies the offending drug and
the reactivity of patch tests in FDE is variable.1
Case Report
A 45-year-old woman presented in May 2005 with multiple,
round, erythematoviolaceous, well-defined plaques, with
central blisters, localized on the trunk, forearms, and dorsum
of the hands. She recounted three previous cutaneous erup-
tions with the same morphologic features in the same sites
that had disappeared spontaneously in 8–10 days leaving
only residual brown to gray hyperpigmentation, a condition
with clinical and evolutionary features typical of FDE. In the
last episode, the patient described the oral intake of 10 mg
cetirizine (Zyrtec®) for allergic rhinitis 4 h before lesional
reactivation, but she did not recall any particular drug intake
before the other episodes. Because of the exuberance of the
lesions, the patient was treated with methylprednisolone,
32 mg/day, with rapid tapering in 8 days.
To confirm the etiology of this FDE, 6 weeks later, when
there were only residual hyperpigmented lesions, patch tests
were performed, according to the guidelines for performing
skin testing in drug eruptions.2 Powdered Zyrtec®, prepared
at 20% in water and petrolatum, and hydroxyzine at 10% in
petrolatum (Chemotechnique) were patch tested using Finn
Chambers on Scanpor tape on both healthy skin of the back
and residual lesions (24 h occlusion and readings at days 2
and 3). Positive results (++) were obtained for Zyrtec® pow-
der and hydroxyzine on residual lesions only (Fig. 1). One
month later, hydroxyzine at 1% in petrolatum (Chemotech-
nique) and powdered Xyzal® (levocetirizine), prepared at
20% in water and petrolatum, induced positive reactions (++)
on residual lesions only at 24 and 48 h (Fig. 2). Other suspi-
cious drugs tested on lesional skin (nimesulide and piroxicam
in 1% petrolatum) gave negative results. No reaction was
observed with the 30 allergens of the Portuguese Contact
Dermatitis Group Standard Series tested on normal back skin.
No relapse was observed when the patient avoided the three
reactive drugs: hydroxyzine, cetirizine, and levocetirizine. No
oral provocation tests were performed.
Discussion
More than 100 drugs have been implicated in FDE; however,
this side-effect is more commonly found with tetracyclines,
sulfonamides, sulfone, penicillins, pyrazolones, barbiturates,
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phenolphthalein, aspirin, and oral contraceptives.3–5 In our
experience, FDE is mainly caused by the nonsteroidal anti-
inflammatory drugs (NSAIDs) piroxicam and nimesulide.2,6–8
It has also been described as a side-effect of some anti-H1-
antihistamine drugs, such as cyclizine lactate, diphen-
hydramine hydrochloride, phenothiazines, hydroxyzine,3 and
loratadine.4,9 Four cases of FDE to cetirizine have been described,
two to cetirizine only,10,11 one to cetirizine and hydroxyzine,1
and one to cetirizine and levocetirizine.3
The pathogenesis of FDE is not completely understood, but
epidermal CD8 T cells retained in lesional skin are believed to
contribute to immunologic “memory,” being reactivated on
re-challenge.1,5,12
Oral challenge can be used to confirm the etiology of FDE;5
however, there are risks involved in this approach, namely
anaphylactic reactions1 or intense lesional reactivation with a
significant increase in the number of lesions.
Patch testing at the site of a previous lesion yields a positive
response in up to 43% of cases.13 Reactivity depends on the
drug and the vehicle, is usually seen before 24 h, and is
observed exclusively on lesional skin. Retained memory-
specific T lymphocytes may play a key role in evoking the
patch test reaction on lesional skin only.10 Patch testing is safer
than oral provocation tests, allows the study of several drugs
at the same time, and can also be interesting in the study of
cross-reactions between drugs, as in previously reported cases.6,7
Cutaneous reactivity to the three H1-antihistamines is
caused by the fact that they have the same chemical piperazine
structure and similar pharmacologic profiles.3 In vivo, 45%
of hydroxyzine is transformed into cetirizine and levoceti-
rizine is the active (R)-enantiomer of cetirizine.3 To the best of
our knowledge, this is the first report of FDE to cetirizine with
positive patch tests to hydroxyzine, cetirizine, and levocetirizine.
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